Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)

NCT01058239 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01058239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01058239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2017
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

epstein barr virus infections, post-transplant lymphoproliferative disease, solid organ transplant, stem cell transplant (bone marrow transplant)